Form 4: Werewolf Therapeutics Director Michael Sherman Granted 27,000 Stock Options

Michael A. Sherman, a Director at Werewolf Therapeutics, Inc., was granted 27,000 stock options with an exercise price of $1.29, aligning his incentives with long-term shareholder value.

Summary

• Michael A. Sherman, a Director of Werewolf Therapeutics, Inc. (HOWL), was granted 27,000 stock options on June 12, 2025.
• The stock options have an exercise price of $1.29 per share.
• The shares underlying the options will vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Sherman's continued service as a director.
• The options are exercisable as of the grant date, June 12, 2025, and are set to expire on June 11, 2035.
• Following this transaction, Mr. Sherman directly beneficially owns 27,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, incentivizing long-term performance. It is a routine compensation event and does not indicate any negative operational or financial issues.

Positives

• The grant of stock options to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance and stock price appreciation.
• The exercise price of $1.29 suggests a potential belief in future stock price growth beyond this level, indicating confidence from the board.

Risks

• The value of the granted stock options is directly tied to the future market performance of Werewolf Therapeutics' common stock; if the stock price does not rise above the $1.29 exercise price, the options may expire worthless.
• The full vesting of the options is subject to Michael A. Sherman's continued service as a director, meaning he must remain in his role to fully realize the potential benefit.

Future Outlook

The vesting schedule for the granted stock options indicates that the director's continued service is required for the options to fully vest, aligning their future commitment with the company's performance and long-term strategic goals.

Industry Context

This Form 4 filing reflects a standard practice of compensating directors with equity, common across the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation. The specific exercise price and number of options granted would typically be determined by the company's compensation committee based on market benchmarks and individual contributions.

Comparison to Industry Standards

• The granting of stock options to directors is a common compensation practice in the biotechnology sector, similar to companies like Moderna (MRNA) or BioNTech (BNTX), where equity incentives are used to attract and retain talent and align interests with long-term growth.
• The specific value and vesting terms of such grants are typically benchmarked against peer companies of similar market capitalization, development stage, and therapeutic focus to ensure competitive and effective compensation.

Related Party Transactions

• Grant of 27,000 stock options to Michael A. Sherman, a Director of Werewolf Therapeutics, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with long-term stock performance and value creation.
• Management/Directors: Michael A. Sherman's compensation package is enhanced, incentivizing his continued service and performance within the company.

Next Steps

• The vesting of the granted stock options will occur on the earlier of June 12, 2026, or the next annual meeting of stockholders, contingent on the director's continued service.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, stock options, director compensation, insider transaction, SEC Form 4, equity grant, Michael A. Sherman, corporate governance